Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sucampo Pharmaceuticals Inc.

www.sucampo.com

Latest From Micromass UK Ltd.

Antibiotics: Start-Ups Ply Novel Targets and Technologies

Microbial drug resistance is a real and growing problem, but drugmakers face disincentives: a plethora of products already on the market, the difficulty of differentiating drugs, and the habit of reserving truly new drugs for emergencies. Big Pharmas are backing out, creating opportunities for small companies who feel they can play successfully. But lack of interest from large partners means biotechs can't access the assets those firms hold, so many start-ups are pairing up with peers. Some firms are building businesses around an abundance of targets derived through genomics. But others are deliberately avoiding working with novel genetic code and instead studying whole cells and physiological changes in organisms. Many firms are addressing the lack of chemical diversity against targets. Some of these are pursuing diversity through natural products like marine microbes, insisting they'll fare better than earlier firms did, in part because of technological advances. Others are trying to create diversity synthetically, by taking structural approaches to understanding targets new and old, as well as compounds. Crystallography, in silico libraries, computational models and mass spectroscopy are key tools in iterative development processes that remain unproven in the anti-infectives field. Some firms are seeking to minimize the risks of novelty, by putting their efforts into developing new versions of antibiotics that worked well before resistance grew. No matter what technological approach start-ups take to developing antibiotics, all face similar challenges external to themselves-primarily in regulatory affairs and funding, but also in hunting Big Pharma partnerships.
BioPharmaceutical Strategy

How Big Can Bio-Rad Get?

Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.
BioPharmaceutical Medical Device

Instrumentomics

Instrumentation manufacturers have become increasingly aware that platforms can be more lucrative than tools. By entering into alliances to create value-added research platforms focused on particular applications, like toxicogenomics or proteomics, they see an opportunity to participate in markets much larger than their traditional research segments.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Dental & Oral Products
  • Dermatology
  • Gastrointestinal
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Sucampo AG
  • Sucampo Group
  • Sucampo Japan AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sucampo Pharmaceuticals Inc.
  • Senior Management
  • Peter Greenleaf, CEO
    Andrew Smith, CFO
    Peter Kiener, CSO
    Matthias Alder, EVP, Bus. Dev. & Licensing
  • Contact Info
  • Sucampo Pharmaceuticals Inc.
    Phone: (301) 961-3400
    805 King Farm Blvd.
    Ste. 550
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register